Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Blood (2017) 130 (4): 472–477.

https://doi.org/10.1182/blood-2017-02-766121

Published: 2017

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Jorge E Romaguera, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Luis E Fayad, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, Pam Weaver, Kim Hartig, Maria Badillo, BS, Larry W. Kwak, MD, PhD, Anas Younes, MD, Barbara Pro, MD, Michael Wang, MD

Blood (2013) 122 (21): 5122.

https://doi.org/10.1182/blood.V122.21.5122.5122

Published: 2013

Journal Articles

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN, Felipe Samaniego, MD, MPH

Blood (2012) 120 (21): 901.

https://doi.org/10.1182/blood.V120.21.901.901

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

Felipe Samaniego, MD, MPH, Jillian F Wise, BS, Rong-Hua Tao, MD, PhD, Haifeng Zhu, PhD, Xue Ao, MS, Zeming Chen, PhD, Wenzhuo Zhuang, PhD, Frank K Braun, PhD, Rohit Mathur, PhD, Jorge Enrique Romaguera, MD, Luis Fayad, MD, Michael Wang, MD, Peter McLaughlin, MD, Timothy J. McDonnell, MD, PhD, Keyur P. Patel, MD, PhD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2012) 120 (21): 2406.

https://doi.org/10.1182/blood.V120.21.2406.2406

Published: 2012

Journal Articles

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Blood (2012) 119 (18): 4123–4128.

https://doi.org/10.1182/blood-2012-01-405456

Published: 2012

Includes: Supplemental data

Journal Articles

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Nathan H. Fowler, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Maria A. Rodriguez, MD, Barbara Pro, MD, F.B. Hagemeister, MD, Anas Younes, MD, Jatin J Shah, MD, Larry W Kwak, MD, PhD, Diana Rodriguez, Peter McLaughlin, MD

Blood (2011) 118 (21): 99.

https://doi.org/10.1182/blood.V118.21.99.99

Published: 2011

Journal Articles

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Nicolas Batty, MD, Elham Ghonimi, MD, Lei Feng, PhD, Anas Younes, MD, Rodriguez Alma, MD, Elizabeth Wager, MD, Fernando Martinez, MD, MPH, Michael Wang, MD, Peter McLaughlin, MD, Nathan Fowler, MD, Fredrick Hagemeister, MD

Blood (2010) 116 (21): 3357.

https://doi.org/10.1182/blood.V116.21.3357.3357

Published: 2010

Journal Articles

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Paul A. Hamlin, Jr, MD, Maria Alma Rodriguez, MD, Ariela Noy, MD, Carol S. Portlock, MD, David Straus, MD, Peter McLaughlin, MD, Barbara Pro, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Brett Wegner, Otilia Dumitrescu, MD, Neetha Pandit Tasker, MD, Craig H Moskowitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2010) 116 (21): 1793.

https://doi.org/10.1182/blood.V116.21.1793.1793

Published: 2010

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.

Anas Younes, MD, Michelle A. Fanale, MD, Peter McLaughlin, MD, Amanda Copeland, Joy Zhu, Silvania de Castro Faria

Blood (2010) 116 (21): 2830.

https://doi.org/10.1182/blood.V116.21.2830.2830

Published: 2010

Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 1714.

https://doi.org/10.1182/blood.V114.22.1714.1714

Published: 2009

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Amanda R Copeland, MS, Yumei Cao, MD, Michelle Fanale, M.D., Luis Fayad, MD, Peter McLaughlin, Barbara Pro, MD, Fredrick Hagemeister, Jorge Romaguera, MD, Felipe Samaniego, MD, Alma Rodriguez, MD, Anas Younes, MD

Blood (2009) 114 (22): 1680.

https://doi.org/10.1182/blood.V114.22.1680.1680

Published: 2009

Journal Articles

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Blood (2009) 114 (22): 868.

https://doi.org/10.1182/blood.V114.22.868.868

Published: 2009

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD

Blood (2009) 114 (22): 588.

https://doi.org/10.1182/blood.V114.22.588.588

Published: 2009

NARROW

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only